Navigator Medicines, Inc. — SEC Form D Filing

Navigator Medicines, Inc. filed an SEC Form D on September 25, 2026, reporting $10.00M raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
September 25, 2026
Amount reported
$10.00M
Round stage
Series A because a ten million dollar raise in the biotechnology sector typically funds the transition from preclinical target validation to IND-enabling studies.
Industry
Biotechnology
Website
https://navigatormedicines.com

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Patients suffering from complex autoimmune and oncology diseases lack highly targeted therapies, resulting in poor treatment outcomes and severe systemic side effects from broad-spectrum treatments.

Solution

Navigator Medicines develops a pipeline of novel, targeted biologic therapies designed to precisely modulate disease pathways and improve patient outcomes.

Why now

Recent advancements in translational medicine and high-throughput screening technologies allow researchers to identify and validate novel disease targets with unprecedented speed and accuracy.

Source: SEC EDGAR Form D filing